In the News

The Latest Breakthrough Approach in Immunity – IMMUSE™ Enters the U.S. Market

The Latest Breakthrough Approach in Immunity – IMMUSE™ Enters the U.S. Market

U.S. launch of the cutting-edge paraprobiotic immune activator ingredient IMMUSE™, supported by ten human trials.

New York, NY – September 28^st, 2020 – International health ingredient manufacturer Kyowa Hakko Bio Co., Ltd. (Kyowa Hakko) and parent company Kirin Holdings Co., Ltd., (Kirin Holdings) announce the launch of its novel dietary supplement ingredient IMMUSE™, delivering a new approach for broad range immune support.

IMMUSE™, a dietary supplement ingredient, is a unique patented strain of Lactococcus lactis strain Plasma characterized as a heat-killed lactic acid bacteria (paraprobiotic) that functions to activate the immune system*. 

IMMUSE™, discovered by Kirin Holdings, a pioneer in fermentation technology, acts uniquely by activating plasmacytoid dendritic cells (pDC).  pDC, the “commander in chief” of the immune system has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, providing broad range immune support.

Supported by ten human trials consisting of eight efficacy studies and two safety studies, IMMUSE™ is a science-supported ingredient that functions to get your immune system ready and support year-round health* when taken regularly. A series of safety data including in vitro, in vivo and in human have been collected.  Deemed stable in a wide variety of applications including tablets, capsules and gummy formulations., IMMUSE™ is already on market as a finished product in Japan, where it is sold in the form of gummies, tablets, yogurt, and functional beverages. Those products were registered with the Consumer Affairs Agency of the Japanese government as a “Food with Function Claims.” The products with IMMUSE will be the first and only products in Japan to display an immune-related function on the product.   

“We could not be more thrilled to integrate the immune support benefits of IMMUSE™ into the US market,” comments Elyse Lovett, MS, MBA, Senior Marketing Manager at Kyowa Hakko U.S.A. Inc. Ms. Lovett added: “A strong immune system is critical for good health, and IMMUSE™ is a unique dietary supplement ingredient that offers broad range immune support *.”

With sales in the US dietary supplement market valued at over $1.52 billion, immune system products are high in demand. As the immune health market continues to boom, Lovett remarks that, “With more consumers looking for ways to enhance their immune system and stay healthy throughout the year, we are confident that IMMUSE™, backed by both Kirin Holdings and Kyowa Hakko, will open new doors for consumers desiring a novel option for brand range immune support.”

Media interested in setting up an interview with a representative from Kyowa Hakko to discuss the launch of IMMUSE™, please contact Sara White at sara@adinnyc.com or 212-693-2150. 

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

About Kyowa Hakko USA 
Kyowa Hakko USA is the North & South American office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals and food products. For more information visit Kyowa-USA.com.